Drug
D1015 | nifuroxazide
A
A07AX03 Nifuroxazide
[A07AX] Other intestinal antiinfectives
[A07A] INTESTINAL ANTIINFECTIVES
[A07] ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
[A] Alimentary tract and metabolism
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 1.57±0.30 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 2.34 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 6.71±1.54 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 388.2 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | EC20 | 36 |
| RESPIRATION | 61.5 µM | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. | decrease | EC20 | 36 |
| RESPIRATION | 3.7 µM | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. | decrease | EC20 | 36 |
| SWELLING | > 400 µM | 30 mins | mouse | liver mitochondria | swelling assay: Absorbance at 545 nm using a fluorescence multi-well plate reader (CaCl2 (50 µM) was considered as the 100% baseline for the swelling ) | increase | EC20 | 36 |
| Target | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| NADH:ubiquinone reductase | 61.5 µM | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. | inhibit | EC20 | 36 |
| Succinate dehydrogenase | 3.7 µM | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. | inhibit | EC20 | 36 |
| Cytochrome c | > 400 µM | 30 mins | mouse | liver mitochondria | Cytochrome c release was evaluated using ELISA kit ( 20 µg/ml Alamethicin was used as 100% baseline) | release | EC20 | 36 |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
 |
Warning |
Aggregated GHS information provided by 6 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. Reported as not meeting GHS hazard criteria by 4 of 6 companies. For more detailed information, please visit ECHA C&L website Of the 2 notification(s) provided by 2 of 6 companies with hazard statement code(s): H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] H312 (50%): Harmful in contact with skin [Warning Acute toxicity, dermal] H332 (50%): Harmful if inhaled [Warning Acute toxicity, inhalation] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P312, P304+P340, P312, P322, P330, P363, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LD50 | intraperitoneal | 1gm/kg (1000mg/kg) | Journal of Pharmacy and Pharmacology. Vol. 16, Pg. 663, 1964. | |
| mouse | LDLo | oral | 6gm/kg (6000mg/kg) | Annales Pharmaceutiques Francaises. Vol. 21, Pg. 287, 1963. | |
| (Nitro-5' furfurylidene-2') hydroxy-4 benzhydrazide | (Nitro-5' furfurylidene-2') hydroxy-4 benzhydrazide [French] | 4-Dydroxy-N-[(E)-(5-nitro-2-furyl)methyleneamino]benzamide |
| 4-Hydroxy-N'-(5-nitrofurfuryliden)benzhydrazid | 4-hydroxy-N'-[(1E)-(5-nitro-2-furyl)methylene]benzohydrazide | 4-hydroxy-N'-[(E)-(5-nitrofuran-2-yl)methylidene]benzohydrazide |
| 4-hydroxy-N-[(E)-(5-nitro-2-furanyl)methylideneamino]benzamide | 4-hydroxy-N-[(E)-(5-nitro-2-furyl)methyleneamino]benzamide | 4-hydroxy-N-[(E)-(5-nitrofuran-2-yl)methylidene]benzenecarbohydrazonic acid |
| 4-hydroxy-N-[(E)-(5-nitrofuran-2-yl)methylideneamino]benzamide | 965-52-6 | 965N526 |
| A845610 | AB00513861 | AB00513861_02 |
| AB00513861_03 | AC-8713 | AKOS000483758 |
| ARONIS016368 | AS-13310 | BDBM50396177 |
| BENZOIC ACID, p-HYDROXY-, (5-NITROFURFURYLIDENE)HYDRAZIDE | BIM-0014420.P001 | BPBio1_000693 |
| BRD-K68188368-001-03-7 | BRN 1352180 | BSPBio_000629 |
| Benzoic acid, 4-hydroxy-, ((5-nitro-2-furanyl)methylene)hydrazide | Benzoic acid, 4-hydroxy-, 2-[(5-nitro-2-furanyl)methylene]hydrazide | Benzoic acid, 4-hydroxy-, [(1E)-(5-nitro-2-furanyl)methylene]hydrazide; |
| C12H9N3O5 | CCG-213989 | CCRIS 5490 |
| CHEBI:135136 | CHEBI:94556 | CHEMBL244888 |
| CS-4918 | D07111 | DB13855 |
| Diarlidan | Diaryl | Dicoferin |
| EINECS 213-522-0 | Ercefurol | Ercefuryl |
| H868 | HMS1569P11 | HMS2096P11 |
| HMS3713P11 | HY-B1436 | LS-37645 |
| MLS000069620 | N-[(E)-(5-nitrofuran-2-yl)methylideneamino]-4-oxidanyl-benzamide | NSC-759261 |
| NSC759261 | Nifuroxazid | Nifuroxazida |
| Nifuroxazida [INN-Spanish] | Nifuroxazide | Nifuroxazide (INN) |
| Nifuroxazide [INN:BAN:DCF] | Nifuroxazide [INN:DCF] | Nifuroxazide, European Pharmacopoeia (EP) Reference Standard |
| Nifuroxazide, VETRANAL(TM), analytical standard | Nifuroxazide-d4 | Nifuroxazidum |
| Nifuroxazidum [INN-Latin] | Opera_ID_40 | PM5LI0P38J |
| Pharmakon1600-01505788 | Prestwick2_000555 | Prestwick3_000555 |
| Prestwick_874 | R.C. 27-109 | RC 27109 |
| RC-27109 | SBI-0014420.P002 | SC-16466 |
| SCHEMBL14608895 | SCHEMBL542542 | SCHEMBL543480 |
| SJ000287313 | SMR000058185 | STK091243 |
| STL454990 | TX-017860 | UNII-PM5LI0P38J |
| W-100139 | YCWSUKQGVSGXJO-NTUHNPAUSA-N | ZINC7997719 |
| p-Hydroxybenzoic acid (5-nitrofurfurylidene)hydrazide | p-Hydroxybenzoic acid 5-nitrofurfurylidene hydrazide | s4182 |
| DrugBank Name | nifuroxazide |
| DrugBank | DB13855 |
| CAS Number | 1188487-83-3, 965-52-6 |
| PubChem Compound | 5337997 |
| KEGG Drug | D07111 |
| ChEBI | 135136 |